Lacosamide Alembic

Lacosamide, the active ingredient in Lacosamide Alembic, is an anticonvulsant presented as an oral formulation for oral use. It is employed to treat partial‑onset seizures in patients with epilepsy, helping to stabilize neuronal excitability by enhancing slow inactivation of voltage‑gated sodium channels. The product complies with European Union pharmaceutical standards and is manufactured under GMP conditions for international distribution.

GNH USA supplies Lacosamide Alembic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity. It is indicated for the following conditions:

- Partial‑onset seizures: reduces frequency and severity of focal seizures. - Epilepsy (adjunctive therapy): provides additional seizure control when used with other antiepileptic drugs. - Refractory focal epilepsy: offers an alternative option for patients who have not responded adequately to other treatments.

Lacosamide may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: persistent tiredness or lack of energy. - Nausea: upset stomach often accompanied by an urge to vomit. - Headache: mild to moderate cranial pain. - Diplopia: transient double vision. - Blurred vision: temporary visual acuity changes.

Serious or Rare Side Effects: - Suicidal ideation: emergence of thoughts of self‑harm. - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmias. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, swelling, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hematologic abnormalities: leukopenia or thrombocytopenia.

When prescribing Lacosamide, clinicians should consider several safety aspects.

- Renal impairment: adjust dose and monitor renal function. - Hepatic impairment: use caution and monitor liver enzymes. - Cardiac conduction disorders: obtain baseline ECG and monitor for PR‑interval changes. - Pregnancy: risk category unknown; use only if potential benefit justifies potential risk. - Concomitant antiepileptics: monitor for additive CNS depression. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma concentrations. - Drugs that prolong PR interval (e.g., class IA antiarrhythmics): may increase risk of cardiac conduction delays.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs: may increase incidence of CNS side effects. - Alcohol: can enhance dizziness and sedation. - Hormonal contraceptives: may reduce contraceptive efficacy, requiring alternative birth control methods.